Simonetta Mocci
Executive Director, Oncology Clinical Development Gilead Sciences
Seminars
Monday 3rd November 2025
Detailing Efforts of ADC Combinations With Standard of Care Therapies to Shape the Future of Cancer Therapies
11:00 am
• Exploring ongoing combination trails with Trodelvy and standard of care therapies across solid tumor indications
• Evaluating rationale and design of Trodelvy and other ADC-immunotherapy combination therapies
• Breaking down the potential: What is the route forward and potential impact of novel ADC combinations?
